Arrowhead Pharmaceuticals Inc

ARWR.US
Healthcare · Biotechnology
85.78
+0.25 (+0.29%)
USD · NASDAQ

Company Information

Company Name
Arrowhead Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US04280A1007
CIK: 0000879407
CUSIP: 042797100
Currency: USD
Full Time Employees: 711
Phone: 626 304 3400
Fiscal Year End: September
IPO Date: Jun 16, 1993
Description:

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Address:

177 East Colorado Boulevard, Pasadena, CA, United States, 91105

People

Directors & Officers

Name Title Year Born
Dr. Christopher R. Anzalone Ph.D. Chairman, CEO & President 1969
Mr. Daniel J. Apel Chief Financial Officer 1966
Mr. Patrick O'Brien J.D., PharmD COO & Secretary 1964
Dr. James C. Hamilton M.D., MBA Chief Medical Officer and Head of R&D 1979
Dr. Mark M. Davis Ph.D. Founder and Founder & Director of Insert Therapeutics Inc & Calando NA
Dr. Tao Pei Ph.D. Chief Scientific Officer NA
Dr. Vincent Anzalone CFA Head of Investor Relations & VP NA
Mr. Howard Lovy Director of Communications NA
Dr. Bruce D. Given M.D. Chief Medical Scientist 1954
Dr. Mark Seefeld Head of Toxicology & VP 1954

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 23, 2026 James C Hamilton N/A Sale 10.00K $75.00 $750.00K
Apr 22, 2026 Daniel Joseph Apel N/A Sale 13.10K $71.35 $934.33K
Mar 05, 2026 James C Hamilton N/A Sale 10.00K $64.19 $641.90K
Jan 05, 2026 James C Hamilton N/A Sale 40.16K $63.11 $2.53M
Jan 05, 2026 Patrick O'brien N/A Sale 49.49K $63.11 $3.12M
Jan 02, 2026 Christopher Richard Anzalone N/A Sale 13.19K $66.10 $871.66K
Dec 29, 2025 Christopher Richard Anzalone N/A Sale 51.73K $69.13 $3.58M
Dec 26, 2025 Mauro Ferrari N/A Sale 7.53K $70.00 $527.10K
Dec 22, 2025 Christopher Richard Anzalone N/A Sale 12.59K $68.44 $861.39K
Dec 19, 2025 Victoria Vakiener N/A Sale 10.04K $67.68 $679.51K
Dec 19, 2025 William D Waddill N/A Sale 8.37K $67.65 $566.03K
Dec 19, 2025 Christopher Richard Anzalone N/A Sale 13.45K $67.66 $909.69K
Dec 19, 2025 Adeoye Y Olukotun N/A Sale 10.00K $67.66 $676.60K
Dec 17, 2025 Christopher Richard Anzalone N/A Sale 85.00K $64.04 $5.44M
Dec 16, 2025 Christopher Richard Anzalone N/A Sale 54.30K $62.58 $3.40M
Dec 15, 2025 Christopher Richard Anzalone N/A Sale 130.00K $68.85 $8.95M
Dec 05, 2025 Michael S Perry N/A Sale 16.25K $61.03 $991.74K
Nov 28, 2025 Mauro Ferrari N/A Sale 8.75K $56.39 $493.41K
Oct 01, 2025 James C Hamilton N/A Sale 20.00K $35.00 $700.00K
Sep 12, 2025 James C Hamilton N/A Sale 15.00K $30.00 $450.00K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 18.16M Mar 31, 2026 12.89% $0.02 -14.81%
Vanguard Group Inc 15.29M Dec 31, 2025 10.86% $0.01 -4.63%
venBio Select Advisor LLC 10.70M Mar 31, 2026 7.60% $6.60 0.71%
FMR Inc 7.27M Mar 31, 2026 5.16% $0.02 11.44%
Vanguard Portfolio Management, LLC 7.15M Mar 31, 2026 5.07% $0.02 0.00%
State Street Corp 6.50M Mar 31, 2026 4.61% $0.01 1.44%
Vanguard Capital Management, LLC 6.03M Mar 31, 2026 4.28% $0.01 0.00%
Geode Capital Management, LLC 4.28M Mar 31, 2026 3.04% $0.02 31.05%
Fred Alger Management, LLC 3.34M Mar 31, 2026 2.37% $0.92 82.35%
Amvescap Plc. 3.28M Mar 31, 2026 2.33% $0.02 498.92%
Vestal Point Capital LP 2.28M Mar 31, 2026 1.62% $3.99 152.78%
Baker Bros Advisors LP 1.99M Mar 31, 2026 1.41% $0.72 -8.41%
The Goldman Sachs Group Inc 1.74M Mar 31, 2026 1.24% $0.01 3.72%
NORGES BANK 1.70M Dec 31, 2025 1.21% $0.01 -11.45%
Northern Trust Corp 1.66M Mar 31, 2026 1.18% $0.01 23.00%
Siren, L.L.C. 1.62M Mar 31, 2026 1.15% $2.81 7.66%
Deerfield Management Co 1.57M Mar 31, 2026 1.12% $1.16 -14.17%
HHG PLC 1.44M Mar 31, 2026 1.02% $0.04 12.23%
UBS Group AG 1.34M Mar 31, 2026 0.95% $0.01 35.35%
UBS Asset Mgmt Americas Inc 1.33M Mar 31, 2026 0.94% $0.02 5.60%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Mid-Cap ETF 4.79M 3.40% ▼ 0.54% Jun 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 4.25M 3.02% ▲ 0.31% Jun 30, 2026
3 Fidelity Growth Compy Commingled Pl S 3.12M 2.22% ▲ 4.15% May 31, 2026
4 Vanguard Small Cap Index 3.07M 2.18% ▲ 0.26% Jun 30, 2026
5 Fidelity Growth Company Fund 2.36M 1.68% ▲ 3.94% May 31, 2026
6 Vanguard Small Cap Growth Index Inv 1.77M 1.26% ▲ 2.79% Jun 30, 2026
7 Invesco S&P MidCap Momentum ETF 1.74M 1.23% ▲ 0.47% Jun 30, 2026
8 Vanguard Institutional Extnd Mkt Idx Tr 1.62M 1.15% ▲ 2.04% Jun 30, 2026
9 State Street® SPDR® S&P® Biotech ETF 1.40M 1.00% ▼ 2.17% Jun 30, 2026
10 Fidelity Small Cap Index 1.34M 0.95% ▲ 0.86% Apr 30, 2026

Financial Highlights

Market Cap: $12.08B
EBITDA: $-196.53M
PEG Ratio: $-1.32
Book Value: $4.37
Earnings/Share: $-2.27
Profit Margin: -48.38%
Operating Margin: -191.57%
ROA (TTM): -7.22%
ROE (TTM): -42.37%
Revenue (TTM): $622.01M
Revenue/Share (TTM): $4.47
Earnings Growth (YOY): 9.80%
Revenue Growth (YOY): -86.40%

Valuation Metrics

Enterprise Value: $11.25B
Trailing P/E: 0.00
Forward P/E: 111.11

Shares Statistics

Shares Outstanding: 140.86M
Shares Float: 122.78M
% Insiders: 367.70%
% Institutions: 8,903.70%
Short % Float: 9.53%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$829.45M
Cost of Goods Sold
adjust
$-23.93M
Gross Profit
subtotal
$829.45M
SG&A
adjust
$-121.92M
R&D
adjust
$-607.16M
Other Operating Expense
adjust
$-2.03M
Operating Income
subtotal
$98.35M
Other / Non-Operating Items
adjust
$-99.98M
Net Income
subtotal
$-1.63M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ARWR.US!